ID   XG-4
AC   CVCL_4800
SY   XG4; XG 4
DR   ArrayExpress; E-TABM-937
DR   cancercelllines; CVCL_4800
DR   Cosmic; 742961
DR   IARC_TP53; 364
DR   Wikidata; Q54994712
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1373872;
RX   PubMed=1753108;
RX   PubMed=8204890;
RX   PubMed=10557056;
RX   PubMed=10936422;
RX   PubMed=21173094;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Characteristics: Produces IgG kappa.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (PubMed=1373872; PubMed=21173094).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1373872;
RA   Mazars G.-R., Portier M., Zhang X.-G., Jourdan M., Bataille R.,
RA   Theillet C., Klein B.;
RT   "Mutations of the p53 gene in human myeloma cell lines.";
RL   Oncogene 7:1015-1018(1992).
//
RX   PubMed=1753108; DOI=10.4049/jimmunol.147.12.4402;
RA   Jourdan M., Zhang X.-G., Portier M., Boiron J.-M., Bataille R.,
RA   Klein B.;
RT   "IFN-alpha induces autocrine production of IL-6 in myeloma cell
RT   lines.";
RL   J. Immunol. 147:4402-4407(1991).
//
RX   PubMed=8204890; DOI=10.1182/blood.V83.12.3654.3654;
RA   Zhang X.-G., Gaillard J.-P., Robillard N., Lu Z.-Y., Gu Z.-J.,
RA   Jourdan M., Boiron J.-M., Bataille R., Klein B.;
RT   "Reproducible obtaining of human myeloma cell lines as a model for
RT   tumor stem cell study in human multiple myeloma.";
RL   Blood 83:3654-3663(1994).
//
RX   PubMed=10557056; DOI=10.1038/sj.leu.2401563;
RA   Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A.,
RA   Shimizu S., Taniwaki M., Ueda R.;
RT   "Detection of MUM1/IRF4-IgH fusion in multiple myeloma.";
RL   Leukemia 13:1812-1816(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=21173094; DOI=10.3324/haematol.2010.033456;
RA   Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D.,
RA   Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "A high-risk signature for patients with multiple myeloma established
RT   from the molecular classification of human myeloma cell lines.";
RL   Haematologica 96:574-582(2011).
//